Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergies, opioid overdose, respiratory diseases, and inflammatory conditions. The company’s SYMJEPI (epinephrine) injection product has received FDA approval for the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection candidate product, ZIMHI, for treating opioid overdose, is currently under FDA review. Adamis is also developing other products targeting acute respiratory diseases such as COVID-19, influenza, asthma, and COPD.